ak 2123 has been researched along with mitomycin in 3 studies
| Studies (ak 2123) | Trials (ak 2123) | Recent Studies (post-2010) (ak 2123) | Studies (mitomycin) | Trials (mitomycin) | Recent Studies (post-2010) (mitomycin) |
|---|---|---|---|---|---|
| 52 | 8 | 5 | 12,893 | 1,738 | 2,808 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goncharova, SA; Kagiia, VT; Konovalova, NP; Raevskaia, TA | 1 |
| Goncharova, SA; Kagiya, TV; Konovalova, NP; Rajewskaya, TA | 1 |
| Konovalova, NP | 1 |
3 other study(ies) available for ak 2123 and mitomycin
| Article | Year |
|---|---|
[The radiosensitizer AK-2123 enhances sensitivity of MDR-tumors to Mitomycin C].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Leukemia P388; Mice; Mitomycin; Radiation-Sensitizing Agents; Triazoles | 2000 |
Nitrotriazole AK-2123 enhances mitomycin C activity in mice bearing multidrug-resistant tumors.
Topics: Animals; Antibiotics, Antineoplastic; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Leukemia P388; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mitomycin; Radiation-Sensitizing Agents; Triazoles | 2001 |
Ultralow doses of various drugs in chemotherapy of experimental tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Indazoles; Leukemia P388; Lung Neoplasms; Melanoma; Mice; Mitomycin; Neoplasm Metastasis; Neoplasms, Experimental; Triazoles; Xenograft Model Antitumor Assays | 2003 |